Clinical Trials
11 trialsNCT04447027 2026-01-30
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03409432 2025-07-25
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT03302728 2022-05-19
EpiBrentlen
Peter MacCallum Cancer Centre, Australia
Phase 1 Completed
NCT00057616 2019-11-08
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
Celgene
Phase 3 Completed
NCT00179608 2019-11-08
Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
Celgene
Phase 1 Completed
NCT01254578 2017-09-25
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
National Cancer Institute (NCI)
Phase 1 Completed
NCT00109005 2017-01-02
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00412581 2016-04-29
Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00031941 2012-03-15
CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00055562 2005-06-24
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
Celgene
Phase 2/3 Completed